ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new weapon in fight against aggressive blood cancer
Disease control OngoingThis early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combi…
Matched conditions: ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New Three-Drug attack on tough lymphomas
Disease control OngoingThis study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly d…
Matched conditions: ANN ARBOR STAGE IV MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC